reference standard is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-25. Numbers and descriptions here follow the published literature rather than marketing material.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
== Anwendung == Der Sputtereffekt wird in der Materialbearbeitung und Analytik für die Reinigung von Werkstoffen und Proben eingesetzt. So kann durch eine Sputterreinigung die Oberfläche von kleinen Partikeln und organischen Verschmutzungen befreit werden, so dass ein nachfolgender Beschichtungsprozess reproduzierbarer erfolgen kann. Ähnliches gilt für die Reinigung von Proben bei oberflächensensitiven Messtechniken, beispielsweise bei der Photoelektronenspektroskopie (UPS, XPS usw.) durch kurzen Beschuss mit Argonionen. Der Sputtereffekt kann aber auch dazu dienen, um Informationen aus tieferen Bereichen zu erhalten. So kann bei Photoelektronenspektroskopie und Sekundärionen-Massenspektrometrie (SIMS) durch abwechselndes bzw. gleichzeitiges Sputtern und Messen ein Tiefenprofil von Schichtsystemen bestimmt werden – dabei müssen jedoch Effekte wie Vorzugssputtern (unterschiedliche Sputterraten für verschiedenschwere Atome) beachtet werden. Die Sputterdeposition ist eine der Standardbeschichtungstechniken und findet vielfältige Anwendung in der Industrie. Die für die Beschichtung verwendbaren Materialien bzw. Materialsysteme unterscheiden sich stark durch das eingesetzte Spezialverfahren. Generell ist die Bandbreite an möglichen Materialien aber sehr groß. Mit „klassischen“ (passiven) Sputterdepositionsverfahren werden hauptsächlich Metalle abgeschieden, beispielsweise Titan, Wolfram und Nickel, aber auch Legierungen mit Nickelaluminium (NiAl) und Nichtmetalle wie Silicium oder Siliciumdioxid (SiO2) sind möglich.
Reaktive Verfahren hingegen ermöglichen durch den Einbau zusätzlicher Komponenten aus dem Gasraum die Abscheidung von Metallverbindungen, beispielsweise Metalloxide wie Aluminiumoxid (Al2O3) mit hoher Präzision in der Stöchiometrie der Schicht. In der Halbleiter- und Mikrosystemtechnik wird das Verfahren vor allem für die Herstellung von dünnen Schichten eingesetzt, beispielsweise Aluminium oder Titannitrid. Aber auch in anderen industriellen Bereichen werden gesputterte Dünnschichten eingesetzt, beispielsweise in der Material- bzw. Oberflächenveredelung (z. B. Spiegel, Autoscheinwerfer, Autofelge) oder in der Optik als funktionelle Schicht (z. B. Dünnschicht-Polarisator, Wärmeschutzglas).
== Nachteile == Generell ist bei der Reinigung der Oberfläche bei empfindlichen Materialien (z. B. Graphit-Einkristallen) durch Sputtern zu bedenken, dass durch das Sputtern die Kristallstruktur (teilweise) zerstört wird. Bei zu starkem Sputtern, also bei zu hoher Energie der Ionen, besteht zusätzlich die Gefahr, dass die noch nicht abgetragenen Schmutzatome in die Oberfläche eingebracht werden (engl. knock-on effect).
Sources: de.wikipedia.org
== Literatur == P. J. Martin: Ion-based methods for optical thin film deposition. In: Journal of Materials Science. Band 21, Nr. 1, 1986, S. 1–25, doi:10.1007/BF01144693. Markus Bautsch: Rastertunnelmikroskopische Untersuchungen an mit Argon zerstäubten Metallen, Kapitel 2.4: Zerstäubung von Oberflächen durch Teilchenbeschuss, Unterkapitel: Zerstäubungsrate – Abtraggeschwindigkeit – Mikrostrukturentstehung – Sekundäre Effekte. Verlag Köster, Berlin 1993, ISBN 3-929937-42-5, S. 18–27.
Sources: de.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.